Literature DB >> 10598011

Cardioprotective activity of endogenous and exogenous nitric oxide on ischaemia reperfusion injury in isolated guinea pig hearts.

E Masini1, D Salvemini, J F Ndisang, P Gai, L Berni, M Moncini, S Bianchi, P F Mannaioni.   

Abstract

BACKGROUND: We evaluated the contribution of endogenous and exogenous nitric oxide (NO) in ischaemia reperfusion (IR) injury and histamine release in the isolated guinea pig heart.
METHODS: Ischaemia reperfusion was performed in isolated Langendorff perfused guinea pig heart throughout the ligature of the left anterior descending coronary (LAD) artery for 20 min, and following the release of the ligature for a further 20 min.
RESULTS: IR promoted a linear release of lactate dehydrogenase (LDH) and a preferential release of histamine in the reperfusion phase. The amount of nitrite (NO2-, one of the breakdown products of NO) released during IR was significantly lower than in the control hearts. These effects were accompanied by an increase in calcium levels and malonyl-dialdehyde (MDA) production in the left ventricle and by a decrease in cardiac mast cell metachromasia. Perfusion of the hearts with two inhibitors of the nitric oxide synthase pathway, namely N(G)-monomethyl-L-arginine (L-NMMA, 10(-4) M) or nitroarginine methylester (L-NAME, 10(-5) M) significantly enhanced histamine and LDH release; these effects were attenuated by co-infusion with L-arginine (10(-4) M) but not D-arginine (10(-4) M), while L-arginine (10(-4) M) alone had no effect. Perfusion of the heart with sodium nitroprusside (SNP), 3-morpholinosydnonimine (SIN-1), glyceryl trinitrate (GTN), all at 10(-5) M, reduced histamine release, LDH release, calcium overload and MDA production induced by IR. These effects were amplified by concomitant perfusion with superoxide dismutase (SOD, 50 IU/ml).
CONCLUSION: The endogenous production of NO provides significant myocardial protection from IR injury and histamine release. These effects were mimicked by various NO donors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10598011     DOI: 10.1007/s000110050504

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  7 in total

1.  Neuroprotective strategies in Parkinson's disease: protection against progressive nigral damage induced by free radicals.

Authors:  C C Chiueh; T Andoh; A R Lai; E Lai; G Krishna
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

Review 2.  Effects of nitrogen monoxide and carbon monoxide on molecular and cellular iron metabolism: mirror-image effector molecules that target iron.

Authors:  Ralph N Watts; Prem Ponka; Des R Richardson
Journal:  Biochem J       Date:  2003-02-01       Impact factor: 3.857

3.  Protective effects of M40403, a selective superoxide dismutase mimetic, in myocardial ischaemia and reperfusion injury in vivo.

Authors:  Emanuela Masini; Salvatore Cuzzocrea; Emanuela Mazzon; Cosimo Marzocca; Pier Francesco Mannaioni; Daniela Salvemini
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

4.  The plant histaminase: a promising enzyme with antioxidant properties versus histamine release in isoprenaline-induced myocardial infarction in rats.

Authors:  Masoud Alirezaei; Bahram Delfan; Omid Dezfoulian; Arash Kheradmand; Hadis Divekan; Marzyeh Rashidipour; Azadeh Khonsari
Journal:  J Physiol Biochem       Date:  2014-09-10       Impact factor: 4.158

5.  Inhibition of anti-IgE mediated human mast cell activation by NO donors is dependent on their NO release kinetics.

Authors:  K H Yip; F P Leung; Y Huang; H Y A Lau
Journal:  Br J Pharmacol       Date:  2009-03-19       Impact factor: 8.739

6.  Mechanisms of the beneficial actions of ischemic preconditioning on subcellular remodeling in ischemic-reperfused heart.

Authors:  By Alison L Müller; Naranjan S Dhalla
Journal:  Curr Cardiol Rev       Date:  2010-11

Review 7.  ArrhythmoGenoPharmacoTherapy.

Authors:  Arpad Tosaki
Journal:  Front Pharmacol       Date:  2020-05-12       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.